Liquid biopsy holds many advantages over solid tumor testing of cancer patients. It is less invasive for the patient, avoiding the need for surgical biopsy, and has improved levels of sensitivity to detect low frequency somatic driver mutations.
The industry is pushing for liquid biopsy to become the go-to method for the collection of clinical DNA samples for oncology genotyping. This could be at the point of diagnosis - for routine monitoring during treatment to detect the appearance of resistance mutations, which may indicate a change of therapy is required. Alternatively, liquid biopsy could be used for future preventative cancer screening of the general population before disease symptoms appear - to facilitate earlier diagnosis and better treatment outcomes.